Suppr超能文献

血管内动脉瘤封堵术中期结果的Meta分析

A Meta-Analysis of Mid-Term Outcomes of Endovascular Aneurysm Sealing.

作者信息

Kouvelos G, Nana P, Brodis A, Spanos K, Tasoudis P, Katsargyris A, Verhoeven E

机构信息

Vascular Surgery Department, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.

Department of Neurosurgery, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece.

出版信息

J Endovasc Ther. 2023 Oct;30(5):664-675. doi: 10.1177/15266028221098706. Epub 2022 Jun 8.

Abstract

BACKGROUND-AIM: Several studies have been published showing conflicting results on the outcome after endovascular aneurysm sealing (EVAS). The aim of the present study is to conduct a systematic review and meta-analysis of published evidence to assess the efficacy of EVAS in the management of patients with abdominal aortic aneurysm (AAA).

METHODS

An electronic search of the English medical literature, from 2010 to March 2021, was conducted using MEDLINE, EMBASE, and Cochrane databases to find studies relevant to outcome after EVAS.

RESULTS

The final analysis included 12 articles published between 2011 and 2021, including 1440 patients. In total, 79.3% of the included patients underwent aneurysm treatment according to the instructions for use. Technical success was 98.8%. Overall, 30-day mortality was 1.3%. Procedure-related complications were reported in 4% of the cohort. During median follow-up of 28.1 months (range 9-72 months), the pooled estimate of endoleak type I, migration and reinterventions was 16% (95% confidence interval [CI]=7-25), 16% (95% CI=9-23), and 19% (95% CI=11-28), respectively. In a sub-analysis, 7 studies (703 patients) reported outcome with a mean follow-up of more than 2 years (range 24-72 months). In these studies, the pooled estimate of endoleak type I, migration, and reinterventions was 25% (95% CI=13-38), 22% (95% CI=19-26), and 27% (95% CI=21-33), respectively.

CONCLUSION

Patients who have been treated with EVAS are in high risk for reintervention especially beyond 2 years following implantation. Close surveillance for patients treated with EVAS is mandatory.

摘要

背景与目的

已有多项研究发表,但关于血管内动脉瘤封堵术(EVAS)后的结果呈现出相互矛盾的结果。本研究的目的是对已发表的证据进行系统评价和荟萃分析,以评估EVAS在腹主动脉瘤(AAA)患者管理中的疗效。

方法

利用MEDLINE、EMBASE和Cochrane数据库对2010年至2021年3月的英文医学文献进行电子检索,以查找与EVAS后结果相关的研究。

结果

最终分析纳入了2011年至2021年发表的12篇文章,共1440例患者。总体而言,79.3%的纳入患者按照使用说明接受了动脉瘤治疗。技术成功率为98.8%。总体30天死亡率为1.3%。4%的队列报告了与手术相关的并发症。在中位随访28.1个月(范围9 - 72个月)期间,I型内漏、移位和再次干预的汇总估计分别为16%(95%置信区间[CI]=7 - 25)、16%(95% CI=9 - 23)和19%(95% CI=11 - 28)。在一项亚分析中,7项研究(703例患者)报告了平均随访超过2年(范围24 - 72个月)的结果。在这些研究中,I型内漏、移位和再次干预的汇总估计分别为25%(95% CI=13 - 38)、22%(95% CI=19 - 26)和27%(95% CI=21 - 33)。

结论

接受EVAS治疗的患者再次干预风险较高,尤其是在植入后2年以上。对接受EVAS治疗的患者进行密切监测是必要的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验